Clinical aspects of systemic amyloid diseases

L Obici, V Perfetti, G Palladini, R Moratti… - Biochimica et Biophysica …, 2005 - Elsevier
Amyloidosis is a protein misfolding disorder in which soluble proteins aggregate as insoluble
amyloid fibrils. Protein aggregates and amyloid fibrils cause functional and structural organ …

Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies

R Albertini, R Moratti, G Luca - Current molecular medicine, 2002 - ingentaconnect.com
Although it has been known for long time that atherosclerosis is associated with lipid
deposition, only recently it has been accepted that the plasmatic concentration of cholesterol, …

Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction

…, L Goffredo, A Bertoletti, C Klersy, A Pecci, R Moratti… - Blood, 2005 - ashpublications.org
Endothelial progenitor cell (EPC) mobilization has been reported following tissue damage,
whereas no data are available regarding the mobilization of hematopoietic progenitor cells (…

Serum N-terminal pro–brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis

…, S Perlini, L Obici, E Ascari, GM d'Eril, R Moratti… - Circulation, 2003 - Am Heart Assoc
Background— Brain natriuretic peptide (BNP) is a marker of ventricular dysfunction and can
be used to assess prognosis in heart failure and after myocardial infarction. Heart …

Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure

…, R Ferrari, A Fucili, R Moratti, R Tramarin… - European heart …, 2005 - academic.oup.com
Aims Anaemia is often observed in patients with chronic heart failure (CHF), and it may be
associated with a worse prognosis. Aim of this study was to identify the individual mechanisms …

A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

…, AD Ho, MV Rosin, R Albertini, R Moratti… - Blood, The Journal …, 2014 - ashpublications.org
The kidney is involved in 70% of patients with immunoglobulin light-chain (AL) amyloidosis,
but little is known on progression or reversibility of renal involvement, and criteria for renal …

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL

…, L Obici, AR Bradwell, GVM D'Eril, R Fogari, R Moratti… - Blood, 2006 - ashpublications.org
N-terminal natriuretic peptide type B (NT-proBNP) is a marker of cardiac dysfunction in light
chain amyloidosis (AL) and a powerful prognostic determinant. Serum NT-proBNP and …

Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine

…, MS Graziani, GV Melzi D'Eril, R Moratti… - Clinical …, 2009 - academic.oup.com
Background: The diagnosis of systemic immunoglobulin light-chain (AL) amyloidosis requires
demonstration of amyloid deposits in a tissue biopsy and amyloidogenic monoclonal light …

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy …

…, A Foli, LZ Bragotti, L Obici, R Moratti… - Blood, The Journal …, 2010 - ashpublications.org
… ), the shrinkage coefficient for calibration (measuring the accuracy of the model, ie, the
agreement between observed outcome and prediction), and the Royston explained variation (R 2 …

[HTML][HTML] Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma

…, C Paglino, F Tagliani, A Boncimino, R Moratti… - Annals of oncology, 2008 - Elsevier
Background A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the
pathogenesis of hepatocellular carcinoma (HCC). Patients and methods We studied both IL…